Screener
Dianthus Therapeutics DNTH CMC Activities — Claseprubart Program Related Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept dnth:ClaseprubartProgramRelatedExpenses.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development expenses: | ||
| Claseprubart program-related expenses: | ||
| Clinical operation activity costs | 14,156 | 11,739 |
| CMC activity costs | 3,713 | 3,811 |
| Preclinical study activity costs | 320 | 1,041 |
| Total claseprubart program-related expenses | 18,189 | 16,591 |
| Discovery expenses | 1,363 | 900 |
| Personnel and related costs | 8,635 | 5,847 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's CMC activities — claseprubart program related expenses?
- Dianthus Therapeutics (DNTH) reported CMC activities — claseprubart program related expenses of $3.71M in Q1 2026.
- What does CMC activities — claseprubart program related expenses mean?
- This metric represents the aggregate costs associated with Chemistry, Manufacturing, and Controls (CMC) activities specifically allocated to the development of the claseprubart therapeutic program. These expenses encompass the processes required to ensure product quality, scalability, and regulatory compliance during clinical development phases. Tracking these costs provides insight into the capital intensity and manufacturing readiness of the specific drug candidate.
Ask your AI about Dianthus Therapeutics's cmc activities — claseprubart program related expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude